Device Trial Radar · NCT04509011
Autofluorescence vs Clinical Assessment of Parathyroid Glands During Thyroid Surgery
Last checked: Nov 19, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
516
Actual
Start
Jan 5, 2021
Primary completion
Oct 1, 2022
Study completion Jul 31, 2023
Sponsor
- Lead sponsor
- Region SkaneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Haukeland University Hospital; Jagiellonian University; Sahlgrenska University Hospital; Hospital Rudolfstiftung
- First posted
- Aug 11, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the investigation is to study if the use of Fluobeam®-LX to identify parathyroid glands through autofluorescence during thyroid surgery, may reduce the risk of postoperative hypoparathyroidism, defined as low PTH in patients undergoing total thyroidectomy
Conditions
- Hypoparathyroidism Postprocedural
Interventions
Fluobeam® LXDevice
Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postoperative level of Parathyroid hormone (PTH)Time frame: First postoperative day
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
Rudolfstiftung
Vienna, Austria
Haukeland University Hospital
Bergen, Norway
Jagiellonian University Medical College
Krakow, Poland
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.